tiprankstipranks
Trending News
More News >
Arcus Biosciences Inc (RCUS)
NYSE:RCUS
US Market
Advertisement

Arcus Biosciences (RCUS) Stock Forecast & Price Target

Compare
488 Followers
See the Price Targets and Ratings of:

RCUS Analyst Ratings

Strong Buy
10Ratings
Strong Buy
9 Buy
1 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Arcus
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RCUS Stock 12 Month Forecast

Average Price Target

$30.70
▲(151.85% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Arcus Biosciences in the last 3 months. The average price target is $30.70 with a high forecast of $52.00 and a low forecast of $12.00. The average price target represents a 151.85% change from the last price of $12.19.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","53":"$53","17.75":"$17.75","29.5":"$29.5","41.25":"$41.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,17.75,29.5,41.25,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.81,13.978461538461538,17.146923076923077,20.315384615384616,23.48384615384615,26.652307692307694,29.82076923076923,32.989230769230765,36.15769230769231,39.326153846153844,42.494615384615386,45.66307692307692,48.83153846153846,{"y":52,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.81,12.34,13.870000000000001,15.4,16.93,18.46,19.990000000000002,21.520000000000003,23.05,24.58,26.11,27.64,29.17,{"y":30.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.81,10.901538461538461,10.993076923076924,11.084615384615384,11.176153846153847,11.267692307692307,11.35923076923077,11.45076923076923,11.542307692307693,11.633846153846154,11.725384615384616,11.816923076923077,11.908461538461538,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.12,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.42,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.94,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.89,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.71,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.81,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$52.00Average Price Target$30.70Lowest Price Target$12.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
$47
Buy
285.56%
Upside
Reiterated
09/03/25
Citi Keeps Their Buy Rating on Arcus Biosciences (RCUS)Arcus Biosciences Valuation: Our 12‐month price target for RCUS is $47 derived using a discounted cash flow (DCF) analysis.
Bank of America Securities Analyst forecast on RCUS
Bank of America Securities
Bank of America Securities
$12
Hold
-1.56%
Downside
Assigned
08/25/25
Arcus Biosciences (RCUS) Receives a Hold from Bank of America Securities
Mizuho Securities Analyst forecast on RCUS
Mizuho Securities
Mizuho Securities
$42$45
Buy
269.16%
Upside
Reiterated
08/18/25
Mizuho Securities Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)RCUS (OP, increasing PT to $45 from $42): Investor focus should start pivoting more heavily to cas. We increase our price target to $45 from $42, due primarily to casdatifan (HIF-2a inccRCC).
Wells Fargo
$26$25
Buy
105.09%
Upside
Reiterated
08/07/25
Arcus Biosciences (RCUS) Gets a Buy from Wells Fargo
Morgan Stanley Analyst forecast on RCUS
Morgan Stanley
Morgan Stanley
$22$23
Buy
88.68%
Upside
Reiterated
08/07/25
Morgan Stanley Keeps Their Buy Rating on Arcus Biosciences (RCUS)
Wedbush
$33
Buy
170.71%
Upside
Reiterated
08/07/25
Wedbush Remains a Buy on Arcus Biosciences (RCUS)
H.C. Wainwright Analyst forecast on RCUS
H.C. Wainwright
H.C. Wainwright
$24
Buy
96.88%
Upside
Reiterated
08/07/25
Positive Buy Rating for Arcus Biosciences Driven by Promising Trial Developments and Strategic Outlook
Barclays Analyst forecast on RCUS
Barclays
Barclays
$14
Buy
14.85%
Upside
Reiterated
08/07/25
Barclays Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)
Truist Financial Analyst forecast on RCUS
Truist Financial
Truist Financial
$32
Buy
162.51%
Upside
Reiterated
08/07/25
Truist Financial Remains a Buy on Arcus Biosciences (RCUS)
Leerink Partners Analyst forecast on RCUS
Leerink Partners
Leerink Partners
$46$52
Buy
326.58%
Upside
Reiterated
08/07/25
Leerink Partners Sticks to Their Buy Rating for Arcus Biosciences (RCUS)
Evercore ISI Analyst forecast on RCUS
Evercore ISI
Evercore ISI
Buy
Reiterated
05/07/25
Analysts Offer Insights on Healthcare Companies: Evolus (NASDAQ: EOLS) and Arcus Biosciences (NYSE: RCUS)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
$47
Buy
285.56%
Upside
Reiterated
09/03/25
Citi Keeps Their Buy Rating on Arcus Biosciences (RCUS)Arcus Biosciences Valuation: Our 12‐month price target for RCUS is $47 derived using a discounted cash flow (DCF) analysis.
Bank of America Securities Analyst forecast on RCUS
Bank of America Securities
Bank of America Securities
$12
Hold
-1.56%
Downside
Assigned
08/25/25
Arcus Biosciences (RCUS) Receives a Hold from Bank of America Securities
Mizuho Securities Analyst forecast on RCUS
Mizuho Securities
Mizuho Securities
$42$45
Buy
269.16%
Upside
Reiterated
08/18/25
Mizuho Securities Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)RCUS (OP, increasing PT to $45 from $42): Investor focus should start pivoting more heavily to cas. We increase our price target to $45 from $42, due primarily to casdatifan (HIF-2a inccRCC).
Wells Fargo
$26$25
Buy
105.09%
Upside
Reiterated
08/07/25
Arcus Biosciences (RCUS) Gets a Buy from Wells Fargo
Morgan Stanley Analyst forecast on RCUS
Morgan Stanley
Morgan Stanley
$22$23
Buy
88.68%
Upside
Reiterated
08/07/25
Morgan Stanley Keeps Their Buy Rating on Arcus Biosciences (RCUS)
Wedbush
$33
Buy
170.71%
Upside
Reiterated
08/07/25
Wedbush Remains a Buy on Arcus Biosciences (RCUS)
H.C. Wainwright Analyst forecast on RCUS
H.C. Wainwright
H.C. Wainwright
$24
Buy
96.88%
Upside
Reiterated
08/07/25
Positive Buy Rating for Arcus Biosciences Driven by Promising Trial Developments and Strategic Outlook
Barclays Analyst forecast on RCUS
Barclays
Barclays
$14
Buy
14.85%
Upside
Reiterated
08/07/25
Barclays Reaffirms Their Buy Rating on Arcus Biosciences (RCUS)
Truist Financial Analyst forecast on RCUS
Truist Financial
Truist Financial
$32
Buy
162.51%
Upside
Reiterated
08/07/25
Truist Financial Remains a Buy on Arcus Biosciences (RCUS)
Leerink Partners Analyst forecast on RCUS
Leerink Partners
Leerink Partners
$46$52
Buy
326.58%
Upside
Reiterated
08/07/25
Leerink Partners Sticks to Their Buy Rating for Arcus Biosciences (RCUS)
Evercore ISI Analyst forecast on RCUS
Evercore ISI
Evercore ISI
Buy
Reiterated
05/07/25
Analysts Offer Insights on Healthcare Companies: Evolus (NASDAQ: EOLS) and Arcus Biosciences (NYSE: RCUS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Arcus Biosciences

1 Month
xxx
Success Rate
7/13 ratings generated profit
54%
Average Return
+3.35%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.85% of your transactions generating a profit, with an average return of +3.35% per trade.
3 Months
xxx
Success Rate
12/25 ratings generated profit
48%
Average Return
-0.25%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 48.00% of your transactions generating a profit, with an average return of -0.25% per trade.
1 Year
Peter LawsonBarclays
Success Rate
10/25 ratings generated profit
40%
Average Return
-6.89%
reiterated a buy rating last month
Copying Peter Lawson's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -6.89% per trade.
2 Years
xxx
Success Rate
6/25 ratings generated profit
24%
Average Return
-17.19%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 24.00% of your transactions generating a profit, with an average return of -17.19% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RCUS Analyst Recommendation Trends

Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
12
13
11
12
10
Buy
2
4
6
4
2
Hold
7
9
10
10
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
26
27
26
20
In the current month, RCUS has received 12 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. RCUS average Analyst price target in the past 3 months is 30.70.
Each month's total comprises the sum of three months' worth of ratings.

RCUS Financial Forecast

RCUS Earnings Forecast

Next quarter’s earnings estimate for RCUS is -$1.28 with a range of -$1.43 to -$1.08. The previous quarter’s EPS was $0.00. RCUS beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year RCUS has Outperformed its overall industry.
Next quarter’s earnings estimate for RCUS is -$1.28 with a range of -$1.43 to -$1.08. The previous quarter’s EPS was $0.00. RCUS beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year RCUS has Outperformed its overall industry.

RCUS Sales Forecast

Next quarter’s sales forecast for RCUS is $24.57M with a range of $17.80M to $49.36M. The previous quarter’s sales results were $160.00M. RCUS beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.33% of the time in the same period. In the last calendar year RCUS has Outperformed its overall industry.
Next quarter’s sales forecast for RCUS is $24.57M with a range of $17.80M to $49.36M. The previous quarter’s sales results were $160.00M. RCUS beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 47.33% of the time in the same period. In the last calendar year RCUS has Outperformed its overall industry.

RCUS Stock Forecast FAQ

What is RCUS’s average 12-month price target, according to analysts?
Based on analyst ratings, Arcus Biosciences Inc’s 12-month average price target is 30.70.
    What is RCUS’s upside potential, based on the analysts’ average price target?
    Arcus Biosciences Inc has 151.85% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RCUS a Buy, Sell or Hold?
          Arcus Biosciences Inc has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Arcus Biosciences Inc’s price target?
            The average price target for Arcus Biosciences Inc is 30.70. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $52.00 ,the lowest forecast is $12.00. The average price target represents 151.85% Increase from the current price of $12.19.
              What do analysts say about Arcus Biosciences Inc?
              Arcus Biosciences Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of RCUS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis